Obi Greenman
Chief Executive Officer presso CERUS CORPORATION
Patrimonio netto: 6 M $ in data 31/03/2024
Profilo
William Mariner Greenman is currently the President, Chief Executive Officer & Director at Cerus Corp.
He previously served as an Independent Director at Aduro BioTech, Inc. and Chinook Therapeutics, Inc. He also held the position of Senior Vice President-Biotech Division at Baxter International, Inc. Mr. Greenman obtained his undergraduate degree from Stanford University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
CERUS CORPORATION
1.75% | 14/03/2024 | 3 181 281 ( 1.75% ) | 6 M $ | 31/03/2024 |
Posizioni attive di Obi Greenman
| Società | Posizione | Inizio |
|---|---|---|
| CERUS CORPORATION | Chief Executive Officer | 21/04/2011 |
Precedenti posizioni note di Obi Greenman
| Società | Posizione | Fine |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Director/Board Member | 11/08/2023 |
| BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | 01/01/1995 |
| CHINOOK THERAPEUTICS, INC. | Director/Board Member | - |
Formazione di Obi Greenman
| Stanford University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BAXTER INTERNATIONAL INC. | Health Technology |
| CERUS CORPORATION | Health Technology |
| Aziende private | 2 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
Chinook Therapeutics, Inc.
 Chinook Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA. | Health Technology |
- Borsa valori
- Insiders
- Obi Greenman
